The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Rapid Response Innovation Awards, 2012Functional Integration of Grafted Human Induced Neuronal (iN) Cells in Parkinson's Disease
Objective/Rationale:
Recently, genetic manipulation of human cells from various organs, e.g. skin, enabled direct generation of human nerve cells (so-called induced neurons – iNs) that potentially can... -
Rapid Response Innovation Awards, 2012Trace Amines and Their Metabolites as Potential Heraldic Markers in Parkinson’s Disease
Objective/Rationale:
Tools for early and unambiguous diagnosis of PD are currently missing and disease symptoms are easily mistaken. On the other hand, prompt recognition of PD subjects may increase... -
Rapid Response Innovation Awards, 2012Intestinal and Nasal Microbiota of Patients with Idiopathic Parkinson's disease
Objective/Rationale:
The cause of Parkinson’s disease is unknown and a reliable biomarker to identify Parkinson’s disease patients as early as possible is urgently needed. Nerve cells near the nose... -
Dyskinesia Challenge, 2012The Role of CK2 in the Development of Levodopa-Induced Dyskinesia in Parkinson’s disease
Promising Outcomes of Original Grant:
In Parkinson’s disease, dopamine-producing neurons degenerate, leading to a lack of dopamine in the brain. This leads to profound changes in the cells which are... -
Rapid Response Innovation Awards, 2012Reversing Pre-existing Pathologies of Dopamine Neurons in an Alpha-synuclein Model
Objective/Rationale:
Alpha-synuclein has been identified to play the central role in Parkinson’s disease. Genome-wide association studies confirm alpha-synuclein as a risk factor for... -
Therapeutics Development Initiative, 2012Anti-parkinsonian and Anti-dyskinetic Efficacy of HE3286 in a Model of Parkinson’s Disease
Objective/Rationale:
HE3286 is an anti-inflammatory drug in phase II clinical trials for other diseases that is being evaluated for treatment of Parkinson’s disease (PD). HE3286 taken orally rapidly...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.